Clinical Trials
Explore Arvinas-Sponsored Clinical Trials
Find trials that may be relevant for you and your patients.
Arvinas Development Program
Explore our development pipeline of PROTAC® protein degraders.
Enrolling Oncology Clinical Trials
Learn more about our enrolling clinical trials.
The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.
Breast Cancer
VERITAC-2
A phase 3, randomized, open-label study of vepdegestrant (ARV-471) vs fulvestrant in patients with ER+/HER2- advanced breast cancer
VERITAC-3
A Phase 3, randomized, open-label, study of vepgedestrant (ARV-471) plus palbociclib vs letrozole plus palbociclib in patients with ER+/HER2- Advanced Breast Cancer
TACTIVE-N
A phase 2, open-label, randomized, non-comparative study of neo-adjuvant vepdegestrant (ARV-471) or anastrozole in postmenopausal women with ER+/HER2- localized breast cancer
TACTIVE-E
A phase 1b open-label study of vepdegestrant (ARV-471) in combination with everolimus in patients with ER+/HER2- advanced or metastatic breast cancer
TACTIVE-U
A phase 1b/2 umbrella study of vepdegestrant (ARV-471) in combination with other anticancer treatments in patients with ER+ advanced or metastatic breast cancer
Prostate Cancer
A phase 1b open-label study of bavdegalutamide (ARV-110) and abiraterone in patients with metastatic prostate cancer
A phase 1/2 open-label study of ARV-766 in patients with metastatic castration-resistant prostate cancer and progression on prior systemic therapies